Highlights

• FY26 statutory NPAT rose 27.5% to $638.7m; underlying NPAT increased 2.9% to $636.8m

• Revenue (excluding net Investment income) grew 9.2% to $9.115bn on premium and membership growth

• Medibank Health profit rose 31.3% to $100.7m — the standout growth segment beyond traditional health insurance

• Fully franked ordinary Dividend increased to 19.2cps for FY26; margins expected to remain broadly stable in FY27

Medibank Private Limited (ASX:MPL) is Australia's largest private health insurer by policyholder numbers, operating the Medibank and ahm Health Insurance brands and serving approximately 4 million Australians with private health insurance coverage. The company was privatised through an ASX listing in 2014 and has since built on its core health insurance Business to develop adjacent healthcare services through its Medibank Health division, which provides nursing at home, mental health services, dental services and employee health programs. Medibank's strategic vision is to evolve from a pure insurer toward a more integrated health and wellbeing company.

Latest Developments

Medibank delivered a solid FY26 result, with revenue excluding net investment income increasing 9.2% to $9.115bn and statutory NPAT rising 27.5% to $638.7m. Underlying NPAT increased 2.9% to $636.8m, while group operating profit rose 6.7% to $813.5m. Medibank Health was particularly strong, with profit increasing 31.3% to $100.7m, highlighting the group's growing Diversification beyond traditional private health insurance. The company increased its fully franked ordinary dividend to 19.2cps for FY26, with management expecting resident health-insurance margins to remain broadly stable heading into FY27.

Industry Context

Australia's private health insurance sector is regulated by the Private Health Insurance Act and overseen by APRA and the Australian Health Practitioner Regulation Agency. Premium increases are subject to government approval under the annual premium round process, which provides revenue visibility but limits pricing flexibility. The industry has benefited from strong membership growth as younger Australians take up health insurance, partly driven by the government's Lifetime Health Cover loading penalty and the Medicare Levy Surcharge incentive. However, the sector faces ongoing pressure from hospital and specialist costs that can drive claims growth above the premium increase rates. Medibank's Medibank Health services division provides a diversification lever.

Key Risks

• Claims cost Inflation above the premium increase approval rate could compress health insurance margins in FY27

• Cyber security risk — Medibank suffered a major cyber breach in 2022, and reputational and regulatory consequences are ongoing

• Government regulatory pressure on private health insurer practices, including premium approval processes

• Medibank Health profitability depending on continued contract wins and service quality in a competitive healthcare services market

• Investment portfolio performance affecting the large investment income component that is excluded from revenue but contributes to NPAT

Key Catalysts to Watch

• Premium increase approval for FY27 being at or above claims inflation, protecting margins

• Medibank Health division growing toward $150–200m of profit, contributing more meaningfully to the group Earnings mix

• Membership growth accelerating, expanding the insured base and the recurring premium income

• Investment income benefiting from sustained higher interest rates on the large fixed-income investment portfolio

• Resolution of residual cyber-related regulatory and legal matters, removing a governance overhang

Conclusion

Medibank (ASX:MPL) has delivered one of the most impressive results in this ASX group, with 27.5% statutory NPAT growth and a standout Medibank Health profit of $100.7m (up 31.3%) demonstrating that the health services diversification strategy is working. The fully franked 19.2cps dividend and stable FY27 Margin guidance make MPL one of the more reliable income and growth combinations available in the ASX healthcare sector. For investors seeking quality, franked income from a healthcare business with structural growth tailwinds, Medibank continues to earn its place on every watchlist.